Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

INTRODUCTION: This randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillus Calmette–Guérin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yu Hwa, Kang, Young Ae, Park, Kwang Joo, Choi, Jae Chol, Cho, Kwan Goo, Ko, Da Yeon, Ahn, Jun Ho, Lee, Boram, Ahn, Eunsol, Woo, Yun Ju, Jung, Kwangsoo, Kim, Nan Yul, Reese, Valerie A., Larsen, Sasha E., Baldwin, Susan L., Reed, Steven G., Coler, Rhea N., Lee, Hyejon, Cho, Sang-Nae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173211/
https://www.ncbi.nlm.nih.gov/pubmed/37166567
http://dx.doi.org/10.1007/s40121-023-00806-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173211/
https://www.ncbi.nlm.nih.gov/pubmed/37166567
http://dx.doi.org/10.1007/s40121-023-00806-0

Ejemplares similares